{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T21:04:01Z","timestamp":1792184641730,"version":"4.4.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,4,1]],"date-time":"2011-04-01T00:00:00Z","timestamp":1301616000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1016\/j.rpsm.2010.10.003","type":"journal-article","created":{"date-parts":[[2011,3,13]],"date-time":"2011-03-13T04:21:38Z","timestamp":1299990098000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Asenapina: un nuevo enfoque para el tratamiento de la man\u00eda"],"prefix":"10.1016","volume":"4","author":[{"given":"N\u00faria","family":"Cruz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpsm.2010.10.003_bib0005","unstructured":"United States Food and Drug Administration. FDA Approves Saphris to Treat Schizophrenia and Bipolar Disorder. Press release, 14 August 2007. [Accessed August 2009] Available in: http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm177401.htm"},{"key":"10.1016\/j.rpsm.2010.10.003_bib0010","unstructured":"Schering-Plough Corporation. Saphris (Asenapine) Sublingual Tablets US Prescribing Information. Revised August 2009. [Accessed August 2009] Available in: http:\/\/www.spfiles.com\/pisaphrisv1.pdf"},{"key":"10.1016\/j.rpsm.2010.10.003_bib0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.31887\/DCNS.2008.10.2\/evieta","article-title":"Acute and long-term treatment of mania","volume":"10","author":"Vieta","year":"2008","journal-title":"Dialogues Clin Neurosci."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0020","unstructured":"Stevenson R, Wolde HT. Update 4 \u2013 Akzo, Pfizer Scrap Asenapine Joint Development. 28 November 2006. [Accessed August 2009] Available in: http:\/\/www.reuters.com\/article\/companyNewsAndPR\/idUSL286087420061128"},{"key":"10.1016\/j.rpsm.2010.10.003_bib0025","unstructured":"United States Food and Drug Administration. Saphris (Asenapine) Sublingual Tablets. Briefing Book. 30 July 2009. [Accessed August 2009] Available in: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM173877.pdf"},{"key":"10.1016\/j.rpsm.2010.10.003_bib0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/0091-3057(90)90298-V","article-title":"Actions of ORG 5222 as a novel psychotropic agent","volume":"35","author":"Costall","year":"1990","journal-title":"Pharmacol Biochem Behav."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0035","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.4088\/JCP.v68n1004","article-title":"Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial","volume":"68","author":"Potkin","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0040","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/0269881107082944","article-title":"Asenapine: a novel psychopharmacologic agent with a unique human receptor signature","volume":"23","author":"Shahid","year":"2009","journal-title":"J Psychopharmacol."},{"issue":"Suppl","key":"10.1016\/j.rpsm.2010.10.003_bib0045","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1007\/BF00442554","article-title":"Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia","volume":"99","author":"Meltzer","year":"1989","journal-title":"Psychopharmacology (Berl)."},{"issue":"2 Suppl","key":"10.1016\/j.rpsm.2010.10.003_bib0050","doi-asserted-by":"crossref","first-page":"106S","DOI":"10.1038\/sj.npp.1395370","article-title":"The role of serotonin in antipsychotic drug action","volume":"21","author":"Meltzer","year":"1999","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0055","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00213-003-1683-8","article-title":"Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders","volume":"174","author":"Roth","year":"2004","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00213-008-1098-7","article-title":"Differential regional and dose-related effects of asenapine on dopamine receptor subtypes","volume":"198","author":"Tarazi","year":"2008","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0065","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1038\/npp.2008.20","article-title":"Asenapine increases dopamine, norepinephrine, and acetylcholine efflux in the rat medial prefrontal cortex and hippocampus","volume":"33","author":"Huang","year":"2008","journal-title":"Neuropsychopharmacology."},{"issue":"Suppl5","key":"10.1016\/j.rpsm.2010.10.003_bib0070","first-page":"40","article-title":"Atypical antipsychotics in bipolar depression: potential mechanisms of action","volume":"66","author":"Yatham","year":"2005","journal-title":"J Clin Psychiatry."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0075","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.pnpbp.2006.06.014","article-title":"Atypical antipsychotics in bipolar depression: neurobiological basis and clinical implications","volume":"31","author":"Brugue","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"issue":"Suppl1","key":"10.1016\/j.rpsm.2010.10.003_bib0080","first-page":"S54","article-title":"A 14 day dose escalation, double-blind, randomized, placebo-controlled study of SB518 in adult patients with schizophrenia [abstract]","volume":"30","author":"Neale","year":"2005","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0085","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.tips.2004.07.002","article-title":"Functional, molecular and pharmacological advances in 5-HT7 receptor research","volume":"25","author":"Hedlund","year":"2004","journal-title":"Trends Pharmacol Sci."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0090","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.pnpbp.2003.09.009","article-title":"Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality","volume":"27","author":"Svensson","year":"2003","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0095","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1359-6446(05)03491-4","article-title":"Dopamine D3 receptor antagonists as therapeutic agents","volume":"10","author":"Joyce","year":"2005","journal-title":"Drug Discov Today."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0100","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00213-009-1570-z","article-title":"Asenapine effects in animal models of psychosis and cognitive function","volume":"206","author":"Marston","year":"2009","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0105","first-page":"85","article-title":"Asenapine improves cognitive function in monkeys repeatedly exposed to the psychotomimetic drug phencyclidine","volume":"81","author":"Jentsch","year":"2006","journal-title":"Schizophr Res."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0110","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/syn.20618","article-title":"Asenapine exerts distinctive regional effects on ionotropic glutamate receptor subtypes in rat brain","volume":"63","author":"Tarazi","year":"2009","journal-title":"Synapse."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0115","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2337\/diabetes.54.5.1552","article-title":"Inhibitory effects of antipsychotics on carbachol-enhanced insulin secretion from perifused rat islets","volume":"54","author":"Johnson","year":"2005","journal-title":"Diabetes."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0120","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1192\/apt.6.5.332","article-title":"Assessment of drug-related movement disorders in Schizophrenia","volume":"6","author":"Gervin","year":"2000","journal-title":"Adv Psychiatr Treat."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s00213-002-1053-y","article-title":"The effects of second-generation antipsychotics on cognitive functioning and psychosocial outcome in Schizophrenia","volume":"162","author":"Weiss","year":"2002","journal-title":"Psychopharmacology (Berl)."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0130","unstructured":"Peeters P, De Greef R, Hulskotte E, et al. Asenapine: an overview of phase I pharmacokinetic studies. 2009. Paris, France, Poster presented at 9th World Congress of Biological Psychiatry, 28 June-2 July 2009."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0135","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.jad.2009.12.028","article-title":"Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial","volume":"122","author":"McIntyre","year":"2010","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0140","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1111\/j.1399-5618.2009.00748.x","article-title":"A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0145","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1399-5618.2009.00749.x","article-title":"Asenapine versus olanzapine in acute mania: a double-blind extension study","volume":"11","author":"McIntyre","year":"2009","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0150","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jad.2010.04.005","article-title":"Asenapine for long-term treatment of bipolar disorder: A double-blind 40-week extension study","volume":"126","author":"McIntyre","year":"2010","journal-title":"J Affect Disord."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0155","unstructured":"Schering-Plough Research Institute. Saphris (Asenapine) Sublingual Tablets. Briefing Document (Background Package). 30 July 2009. [Accessed August 2009] Available in: http:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/PsychopharmacologicDrugsAdvisoryCommittee\/UCM173876.pdf"},{"key":"10.1016\/j.rpsm.2010.10.003_bib0160","series-title":"The Maudsley Prescribing Guidelines","author":"Taylor","year":"2009"},{"key":"10.1016\/j.rpsm.2010.10.003_bib0165","unstructured":"Summary of opinion 1 (initial authorisation) Committee for medicinal products for human use (CHMP); 24 June 2010 EMA\/CHMP\/397789\/2010."},{"key":"10.1016\/j.rpsm.2010.10.003_bib0170","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1017\/S1461145710000477","article-title":"Antipsychotics in bipolar depression: in reply","volume":"13","author":"Vieta","year":"2010","journal-title":"Int J Neuropsychopharmacol."}],"container-title":["Revista de Psiquiatr\u00eda  y Salud Mental"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188898911100005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S188898911100005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:25:40Z","timestamp":1761823540000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S188898911100005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,4]]}},"alternative-id":["S188898911100005X"],"URL":"https:\/\/doi.org\/10.1016\/j.rpsm.2010.10.003","relation":{},"ISSN":["1888-9891"],"issn-type":[{"value":"1888-9891","type":"print"}],"subject":[],"published":{"date-parts":[[2011,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asenapina: un nuevo enfoque para el tratamiento de la man\u00eda","name":"articletitle","label":"Article Title"},{"value":"Revista de Psiquiatr\u00eda  y Salud Mental","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpsm.2010.10.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 SEP y SEPB. Published by Elsevier Espa\u00f1a S.L. All rights reserved.","name":"copyright","label":"Copyright"}]}}